Lv5
850 积分 2025-04-23 加入
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
3天前
已完结
Cellular neighborhoods in cancer
21天前
已完结
HER2 and urothelial carcinoma: current understanding and future directions
1个月前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
1个月前
已完结
Tumour heterogeneity and resistance to cancer therapies
2个月前
已完结
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity
3个月前
已完结
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial
3个月前
已完结
Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics
3个月前
已完结
Interrogation of clonal tracking data using barcodetrackR
3个月前
已完结
Altered propionate metabolism contributes to tumour progression and aggressiveness
4个月前
已完结
皖公网安备34019202002308
